Clinical trial · no report yet · Phase 2
ROME
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- NCT04591431 ↗
- Unknown
- Fondazione per la Medicina Personalizzata
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 36 | |
| YouTube | 6 | |
| Podcasts | 6 | |
| Bluesky threads | 3 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
- Interventions
- Erlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab; Lapatinib; Everolimus; Vemurafenib; Cobimetinib; Alectinib; Brigatinib; Palbociclib; Ponatinib; Vismogedib; Itacitinib; Ipatasertib; Entrectinib; Atezolizumab; Nivolumab; Ipilimumab; Pemigatinib; Oncology Drugs; Pralsetinib; Selpercatinib; Talazoparib; Tepotinib; Alpelisib
- Arms
- Tailored Therapy · Experimental
- Standard of Care · Active comparator
- Enrollment
- 400
- Primary outcomes
- OVERALL RESPONSE RATE (ORR)
- Sponsor
- Fondazione per la Medicina Personalizzata
- Start
- Oct 7, 2020
- Primary completion
- Dec 2024 (estimated)
- Results posted
- No
- Registry record
- NCT04591431 · updated Oct 3, 2023
Publications
linked from the registry- Marchetti P, Curigliano G, Westphalen CB, Biffoni M, Lonardi S, Scagnoli S, Fornaro L, Guarneri V, De Giorgi U, Ascierto PA, Blandino G, D'Amati G, Aglietta M, Cremolini C, Conte P, Crimini E, Ceracchi M, Pisegna S, Verkhovskaia S, Bordonaro R, Bracarda S, Butturini G, Del Mastro L, DeCensi A, Fabbri A, De Galitiis F, Fenocchio E, Gori S, Metro G, Pessino A, Pozzessere D, Puglisi F, Tamberi S, Zambelli A, Marino D, Capoluongo E, Cappuzzo F, Cerbelli B, Giannini G, Malapelle U, Mazzuca F, Nuti M, Pruneri G, Simmaco M, Strigari L, Tonini G, Savarese A, Adamo V, Quaresmini D, Tagliaferri P, Damiano P, Urbini B, Bengala C, Zaffignani E, Pinto C, Tosoni A, Buffoni L, Maiello E, Mucciarini C, Russo A, Berardi R, Lombardi G, Piancastelli A, Masi G, Bonanno L, Vanella V, Mannozzi F, Martini N, Botticelli A. The role of the molecular tumor board: learnings from the ROME trial. NPJ Precis Oncol. 2026 Apr 10;10(1):213. doi: 10.1038/s41698-026-01386-1. PubMed 41963505
- Marchetti P, Curigliano G, Biffoni M, Lonardi S, Scagnoli S, Fornaro L, Guarneri V, De Giorgi U, Ascierto PA, Blandino G, D'Amati G, Aglietta M, Cremolini C, Conte P, Crimini E, Ceracchi M, Pisegna S, Verkhovskaia S, Bordonaro R, Bracarda S, Butturini G, Del Mastro L, DeCensi A, Fabbri A, Fenocchio E, Gori S, Metro G, Pessino A, Pozzessere D, Puglisi F, Tamberi S, Zambelli A, Marino D, Capoluongo E, Cappuzzo F, Cerbelli B, Giannini G, Malapelle U, Mazzuca F, Nuti M, Pruneri G, Simmaco M, Strigari L, Tonini G, Martini N, Botticelli A; ROME trial investigators consortia. Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial. Nat Med. 2025 Oct;31(10):3514-3523. doi: 10.1038/s41591-025-03918-x. Epub 2025 Sep 29. PubMed 41023484